2 completed, 1 suspended, 1 terminated, 1 unknown. 6 Phase 3, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 6 | Completed 2, Suspended 1, Terminated 1, Unknown 1, Withdrawn 1 |
| Phase 2 | 1 | Suspended 1 |
Follow Placebo Oil: new trials by email Literature Review of Placebo Oil trials Research Report on Placebo Oil
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Cannabinoids for the Treatment of Anxiety Disorders: An 8-Week Pilot Study 50:2 mg(CBD:THC)/ml - Cannabinoid Oil Oral Preparation- titrated as tolerated up to a maximum 8mls twice daily (200 mg- 800 mg total dose), Placebo Oil - Generalized Anxiety Disorder, Social Anxiety Disorder | Phase 3 | Withdrawn | McMaster University | 2021-04-01 | 2021-03-24 | |
| CBD Oil for Reducing Emotional Impact of COVID-19 CBD Isolate, Full Spectrum CBD Oil, Broad-Spectrum CBD Oil - Anxiety Depression, Alcohol Abuse | Phase 2 / Phase 3 | Suspended | University of Texas at Austin | 200 | 2020-12-04 | 2023-11-22 |
| High-Dose Vitamin D3 Supplementation in the Treatment of Human Immune Deficiency Virus Patients Trial placebo Oil, 25-Hydroxyvitamin D - HIV-1-infection, Hypovitaminosis D | Phase 3 | Completed | University of the Punjab | 95 | 2019-02-15 | 2022-04-11 |
| Efficacy of Cannabinoids in Amyotrophic Lateral Sclerosis or Motor Neurone Disease MediCabilis CBD Oil, Placebo Oil - Amyotrophic Lateral Sclerosis, Motor Neuron Disease | Phase 3 | Unknown | Gold Coast Hospital and Health Service | 17 | 2019-01-09 | 2023-04-03 |
| The Omega-3 Fatty Acid Paediatric Depression Trial Omega 3 fatty acid, Placebo oil - Depression | Phase 3 | Completed | Gregor Berger | 257 | 2017-04-28 | 2023-04-06 |
| RCT of Progesterone to Prevent Preterm Birth in Nulliparous Women With a Short Cervix 17 alpha-hydroxyprogesterone caproate, Placebo Oil - Preterm Delivery, Cervical Length | Phase 3 | Terminated | The George Washington University Biostatistics Center | 657 | 2007-04-01 | 2019-07-15 |
Agoraphobia (1) · Alcoholism (1) · Amyotrophic Lateral Sclerosis (1) · Anxiety Disorders (1) · COVID-19 (1) · Depression (1) · Fractures, Stress (1) · Generalized Anxiety Disorder (1) · Marijuana Abuse (1) · Motor Neuron Disease (1) · Panic Disorder (1) · Parasomnias (1) · Phobia, Social (1) · Premature Birth (1) · Substance-Related Disorders (1)
Gold Coast Hospital and Health Service (1) · Gregor Berger (1) · McMaster University (1) · The George Washington University Biostatistics Center (1) · University of Texas at Austin (1) · University of the Punjab (1)
United States (2) · Australia (1) · Canada (1) · Pakistan (1) · Switzerland (1)
Klaus Schmeck, MD (1) · Menachem Miodovnik, MD (1) · Michael J Telch, Ph.D. (1) · Michael Van Ameringen, MD, FRCPC (1) · Susanne Walitza, MD (1) · William Grobman, MD, MBA (1)
PMID 23010094, PMID 31719072, PMID 31827448, PMID 37425294, PMID 40061518, PMID 40894517, PMID 41481294
2016 (1), U10HD021410 (1), U10HD027869 (1), U10HD027915 (1), U10HD027917 (1), U10HD034116 (1), U10HD034136 (1), U10HD034208 (1), U10HD036801 (1), U10HD040485 (1), U10HD040500 (1), U10HD040512 (1), U10HD040544 (1), U10HD040545 (1), U10HD040560 (1)